Related Experiment Video
Updated: May 6, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
[Intralesional rituximab for refractory granuloma faciale]
Lea Braun1, Christoph Löser2, Mindaugas Andrulis3
1Hautklinik Ludwigshafen, Klinikum der Stadt Ludwigshafen, Bremserstr. 79, 67063, Ludwigshafen, Deutschland. braunle@klilu.de.
Abstract:
A 60-year-old man presented with refractory granuloma faciale. After unsuccessful treatment with dapsone, hydroxychloroquine, and radiotherapy, treatment with intralesional rituximab was initiated. This led to a steady improvement in the lesions without serious side effects. The case shows that rituximab can be a treatment option for refractory cases of granuloma faciale, especially in the context of IgG 4-related autoimmune disease.
More Related Videos
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
03:47Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
Published on: September 27, 2024
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy